Vytorin, a drug used to treat cholesterol does not cause cancer according to a recent research study. Research however pointed out that this drug which is used to lower levels of cholesterol has no impact on cardiovascular diseases.
This report follows the results from a study recently published which pointed out that Vytorin (ezetimibe) aids in development of cancer. This research was based on the fact that 101 patients who were on Vytorin developed cancer as compared to 65 people who were in the control group. Out of these 65, 23 of them in the control group survived while 39 of them who were on Vytorin succumbed to the disease.
A three-study analysis in the September issue of the ‘New England Journal of Medicine’ suggested that there was no strong evidence of a connection between vytorin and cancer. According to the same study, Vytorin with a statin also did not aid in the treatment of cardiovascular diseases including unnatural aortic valve narrowing known as aortic stenosis.
Researchers from the Oxford University reviewed in a statement that there was no conclusive evidence of any effect of Vytorin on cancer rates. Analyzing the three-ezetimibe trials proved this.
There was no increase in the death rate from any specific cancer type nor was there an increase cancer of a particular category according to the results of this trial. Review by the Oxford researchers was conducted with the help of the SHARP and IMPROVEIT studies which is in process now.
